|
US6017922A
|
|
Thermally stable trimetrexates and processes for producing the same
|
|
US6017921A
|
|
Crystalline trimetrexate salts and the process for making the same
|
|
US5994409A
|
|
Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
|
|
US6051563A
|
|
Methods for the administration of amifostine and related compounds
|
|
US5846958A
|
|
Methods of using aminothiols to promote hematopoietic progenitor cell growth
|
|
US5424471A
|
|
Crystalline amifostine compositions and methods of the preparation and use of same
|
|
SG47101A1
|
|
Crystalline amifostine compositions and methods for the preparation and use of same
|
|
US5292497A
|
|
Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate
|
|
US5824664A
|
|
Suppression of HIV expression by organic thiophosphate
|
|
IL105090D0
|
|
N-(phosphonoacetyl)-l-aspartic acid as broad spectrum antiviral
|
|
ZA9301934B
|
|
Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
|
|
WO9014007A1
|
|
Method for protection from azt side effects and toxicity
|
|
US4957481A
|
|
Photodynamic therapeutic technique
|
|
AU3194089A
|
|
Method for protection from chemotherapeutic side effects
|
|
AU2922389A
|
|
Improving toxicity profiles in chemotherapy
|
|
CA1336504C
|
|
Photodynamic therapeutic technique
|
